The Online Investor

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Thu., Feb. 27, 3:50 PM

Slide #14. Catalyst Biosciences, Inc. Secondary Offering

Company: Catalyst Biosciences, Inc. (NASDAQ:CBIO)
Date announced: 2/13/2020
Shares Offered: 4,615,385
Date of Pricing: 2/13/2020
Price Per Share: $6.50
Secondary Offering Details: Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage biopharmaceutical company developing novel treatments for hemophilia and other rare bleeding disorders, (the Company), today announced the pricing of an underwritten public offering of 4,615,385 shares of its common stock, offered at a price of $6.50 per share to the public. Additionally, the Company has granted the underwriters a 30-day option to purchase up to an additional 692,307 shares of its common stock. All of the shares in the offering are being offered by the Company. The offering is expected to close on or about February 18, 2020, subject to customary closing conditions.

Catalyst Biosciences is a clinical-stage biotechnology company focused on developing medicines to address hematology indications, including the treatment of hemophilia. Co. is focusing its product development efforts in the fields of hemostasis (the process that regulates bleeding). Co.'s principal product candidate is Factor VIIa (MarzAA), a Factor VIIa variant. MarzAA is being developed for the prophylactic treatment of individuals with hemophilia A and B with inhibitors. Co.'s second product candidate is Factor IX variants, a subcutaneously dosed Factor IX drug for the prophylactic treatment of individuals with hemophilia B.
Open the CBIO Page at The Online Investor »

Company Name: 
Catalyst Biosciences Inc
Website: 
www.catalystbiosciences.com
Sector: 
Drugs & Pharmaceuticals
Number of ETFs Holding CBIO: 
4
Total Market Value Held by ETFs: 
$3.49M
Total Market Capitalization: 
$75.00M
% of Market Cap. Held by ETFs: 
4.65%
 

Open the CBIO Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes



Strong Buy (4.00 out of 4)
96th percentile
(ranked higher than approx. 96% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2020, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.